Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia

Published:2017-11-02 Issue:18 Volume:130 Page:2006-2017
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zurli Vanessa¹,Wimmer Giuliana¹,Cattaneo Francesca¹,Candi Veronica²,Cencini Emanuele²,Gozzetti Alessandro²,Raspadori Donatella²,Campoccia Giuseppe³,Sanseviero Francesca¹,Bocchia Monica²^ORCID,Baldari Cosima Tatiana¹^ORCID,Kabanova Anna¹^ORCID

Affiliation:

1. Department of Life Sciences and

2. Hematology Unit, University of Siena, Siena, Italy; and

3. Department of Immune Hematology and Transfusion Medicine, University Hospital of Siena, Siena, Italy

Abstract

Key Points ILT3 is ectopically expressed on mature CLL cells and CLL progenitors in the bone marrow. ILT3 controls the activation of Akt kinase in CLL and contributes to a regulatory network defined by a SHIP-1/Deltex1 axis.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/18/2006/1403561/blood775858.pdf

Reference53 articles.

1. Binet’s staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia;Vasconcelos;J Clin Oncol,2003

2. From pathogenesis to treatment of chronic lymphocytic leukaemia;Zenz;Nat Rev Cancer,2010

3. B cell receptor signaling in chronic lymphocytic leukemia;Burger;Trends Immunol,2013

4. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA;Chu;Blood,2008

5. Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells;Binder;PLoS One,2010

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Robust and cost‐effective CRISPR/Cas9 gene editing of primary tumor B cells in Eµ‐TCL1 model of chronic lymphocytic leukemia;HemaSphere;2024-08

2. LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway;Journal of Experimental & Clinical Cancer Research;2024-07-01

3. LILRB4 Checkpoint for Immunotherapy: Structure, Mechanism and Disease Targets;Biomolecules;2024-02-04

4. RelB contributes to the survival, migration and lymphomagenesis of B cells with constitutively active CD40 signaling;Frontiers in Immunology;2022-08-30

5. LILRB4, an immune checkpoint on myeloid cells;Blood Science;2022-04